Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H7N9 Avian Influenza VLP Vaccine
- Development stage
- Unknown
- Lead developer
- Novavax
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous, Intranasal
01
Overview
The **H7N9 Avian Influenza VLP Vaccine** is a virus-like particle (VLP) vaccine designed to protect against avian influenza A (H7N9) virus, a highly pathogenic strain posing pandemic risk. VLPs mimic the virus structure with hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) proteins but lack genetic material, enabling non-infectious immunogenicity via native antigen presentation that induces hemagglutination inhibition (HAI) antibodies, cross-reactive responses, and T-cell immunity. Developed using insect cell systems like Sf9, it has shown protection in preclinical models (mice, ferrets, chickens) against homologous and heterologous H7N9 challenges, with superior efficacy when adjuvanted (e.g., ISCOMATRIX, Matrix-M1). Novavax advanced it to Phase I trials (NCT01897701, NCT02078674), demonstrating safety and immunogenicity, especially with adjuvant boosting seroconversion to 80.6% at low doses. Vaxxas' HD-MAP patch-delivered version (VXS-1219) completed Phase I enrollment in 2024 with BARDA funding for pandemic preparedness.
- Other names
- VXS-1219VXS1219VXS 1219
02
Targets
N9 NA (Influenza A neuraminidase N9)HA (Hemagglutinin)
Beyond the preview
Go deeper on H7N9 Avian Influenza VLP Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H7N9 Avian Influenza VLP Vaccine.